# Avi Orr-Urtreger

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 168 papers | 6,723 citations | 45 h-index | 76 g-index |
| 171 ext. papers | 7,625 ext. citations | 5.3 avg, IF | 5.18 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 168 | Glucocerebrosidase Activity Is Not Associated with Parkinson Disease Risk or Severity.. *Movement Disorders*, **2022**, | 7 | 1 |
| 167 | Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers.. *Npj Parkinsonls Disease*, **2022**, 8, 20 | 9.7 | 0 |
| 166 | PARK16 locus: Differential effects of the non-coding rs823114 on Parkinson disease risk, RNA expression, and DNA methylation. *Journal of Genetics and Genomics*, **2021**, 48, 341-345 | 4 | 1 |
| 165 | The Effect of GBA Mutations and APOE Polymorphisms on Dementia with Lewy Bodies in Ashkenazi Jews. *Journal of Alzheimerls Disease*, **2021**, 80, 1221-1229 | 4.3 | 5 |
| 164 | The GBA-370Rec Parkinson disease risk haplotype harbors a potentially pathogenic variant in the mitochondrial gene SLC25A44. *Molecular Genetics and Metabolism*, **2021**, 133, 109-112 | 3.7 | 0 |
| 163 | R869C mutation in molecular motor gene is involved in dementia with Lewy bodies. *Alzheimerls and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12143 | 5.2 | 0 |
| 162 | Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers. *Journal of Parkinsonls Disease*, **2021**, 11, 1285-1296 | 5.3 | 4 |
| 161 | -GC Intermediate Repeats and Parkinson Disease; A Data-Driven Hypothesis. *Genes*, **2021**, 12, | 4.2 | 2 |
| 160 | Glucocerebrosidase Activity is not Associated with Parkinson Disease Risk or Severity. *Movement Disorders*, **2021**, | 7 | 4 |
| 159 | Biochemical markers for severity and risk in GBA and LRRK2 Parkinson disease. *Journal of Neurology*, **2021**, 268, 1517-1525 | 5.5 | 0 |
| 158 | Tossing and Turning in Bed: Nocturnal Movements in Parkinson Disease. *Movement Disorders*, **2020**, 35, 959-968 | 7 | 13 |
| 157 | A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson Disease. *Movement Disorders*, **2020**, 35, 1249-1253 | 7 | 16 |
| 156 | A novel mutation in segregates with amyotrophic lateral sclerosis in a large family with early onset and fast progression. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2020**, 21, 280-285 | 3.6 | |
| 155 | Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson Progression Markers Initiative (PPMI): a cross-sectional study. *Lancet Neurology, The*, **2020**, 19, 71-80 | 24.1 | 37 |
| 154 | Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson disease. *Scientific Reports*, **2020**, 10, 9329 | 4.9 | 11 |
| 153 | Clinical Observation: Effect of a Second Transpositioned Variant in a Family with Autosomal Dominant Ryanodine Receptor-1-Related Disease. *Journal of Pediatric Genetics*, **2020**, 9, 121-124 | 0.7 | |
| 152 | Feasibility and safety of lumbar puncture in the Parkinson disease research participants: Parkinson Progression Marker Initiative (PPMI). *Parkinsonism and Related Disorders*, **2019**, 62, 201-209 | 3.6 | 9 |

| | | | |
|---|---|---|---|
| 151 | Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson Disease. *Frontiers in Neurology*, **2019**, 10, 531 | 4.1 | 11 |
| 150 | Rare homozygosity in amyotrophic lateral sclerosis suggests the contribution of recessive variants to disease genetics. *Journal of the Neurological Sciences*, **2019**, 402, 62-68 | 3.2 | 4 |
| 149 | The role of the nAChR subunits , , and  on synaptic transmission in the mouse superior cervical ganglion. *Physiological Reports*, **2019**, 7, e14023 | 2.6 | 6 |
| 148 | Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers. *Human Brain Mapping*, **2019**, 40, 2546-2555 | 5.9 | 11 |
| 147 | Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation. *Brain Imaging and Behavior*, **2019**, 13, 1009-1020 | 4.1 | 13 |
| 146 | Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson disease risk?. *Molecular Genetics and Metabolism*, **2019**, 128, 470-475 | 3.7 | 16 |
| 145 | Distinguishing Dementia With Lewy Bodies From Alzheimer Disease: What is the Influence of the GBA Genotype in Ashkenazi Jews?. *Alzheimer Disease and Associated Disorders*, **2019**, 33, 279-281 | 2.5 | 1 |
| 144 | High frequency of C9orf72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis patients from two founder populations sharing the same risk haplotype. *Neurobiology of Aging*, **2018**, 64, 160.e1-160.e7 | 5.6 | 7 |
| 143 | Progression in the LRRK2-Asssociated Parkinson Disease Population. *JAMA Neurology*, **2018**, 75, 312-319 | 17.2 | 58 |
| 142 | Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. *Nature Medicine*, **2018**, 24, 1867-1876 | 50.5 | 105 |
| 141 | Survival rates among Parkinson disease patients who carry mutations in the LRRK2 and GBA genes. *Movement Disorders*, **2018**, 33, 1656-1660 | 7 | 8 |
| 140 | Parkinson disease phenotype is influenced by the severity of the mutations in the GBA gene. *Parkinsonism and Related Disorders*, **2018**, 55, 45-49 | 3.6 | 51 |
| 139 | Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson Disease and Their First-Degree Unaffected Relatives. *Brain Topography*, **2018**, 31, 1029-1036 | 4.3 | 11 |
| 138 | A "dose" effect of mutations in the GBA gene on Parkinson disease phenotype. *Parkinsonism and Related Disorders*, **2017**, 36, 47-51 | 3.6 | 60 |
| 137 | Two Ethnic Clusters with Huntington Disease in Israel: The Case of Mountain Jews and Karaites. *Neurodegenerative Diseases*, **2017**, 17, 281-285 | 2.3 | 3 |
| 136 | Variable PARK2 Mutations Cause Early-Onset Parkinson Disease in a Small Restricted Population. *Journal of Molecular Neuroscience*, **2017**, 63, 216-222 | 3.3 | 1 |
| 135 | Estimation of genetic risk function with covariates in the presence of missing genotypes. *Statistics in Medicine*, **2017**, 36, 3533-3546 | 2.3 | 1 |
| 134 | A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers. *Brain Structure and Function*, **2017**, 222, 1207-1218 | 4 | 13 |

| | | | |
|---|---|---|---|
| 133 | Down-regulation of B cell-related genes in peripheral blood leukocytes of Parkinson disease patients with and without GBA mutations. *Molecular Genetics and Metabolism*, **2016**, 117, 179-85 | 3.7 | 15 |
| 132 | Arm swing as a potential new prodromal marker of Parkinson disease. *Movement Disorders*, **2016**, 31, 1527-1534 | 7 | 80 |
| 131 | Intact working memory in non-manifesting LRRK2 carriers--an fMRI study. *European Journal of Neuroscience*, **2016**, 43, 106-12 | 3.5 | 14 |
| 130 | A founder mutation in ADAMTSL4 causes early-onset bilateral ectopia lentis among Jews of Bukharian origin. *Molecular Genetics and Metabolism*, **2016**, 117, 38-41 | 3.7 | 6 |
| 129 | OPTN 691_692insAG is a founder mutation causing recessive ALS and increased risk in heterozygotes. *Neurology*, **2016**, 86, 446-53 | 6.5 | 32 |
| 128 | A Personalized Approach to Parkinson Disease Patients Based on Founder Mutation Analysis. *Frontiers in Neurology*, **2016**, 7, 71 | 4.1 | 16 |
| 127 | SEPT14 Is Associated with a Reduced Risk for Parkinson Disease and Expressed in Human Brain. *Journal of Molecular Neuroscience*, **2016**, 59, 343-50 | 3.3 | 9 |
| 126 | High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews. *JAMA Neurology*, **2016**, 73, 1448-1453 | 17.2 | 38 |
| 125 | Interest in genetic testing in Ashkenazi Jewish Parkinson disease patients and their unaffected relatives. *Journal of Genetic Counseling*, **2015**, 24, 238-46 | 2.5 | 15 |
| 124 | Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. *Neurology*, **2015**, 85, 89-95 | 6.5 | 92 |
| 123 | Differential effects of severe vs mild GBA mutations on Parkinson disease. *Neurology*, **2015**, 84, 880-7 | 6.5 | 198 |
| 122 | LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis. *Parkinsonism and Related Disorders*, **2015**, 21, 778-82 | 3.6 | 22 |
| 121 | Role of 5-containing nicotinic receptors in neuropathic pain and response to nicotine. *Neuropharmacology*, **2015**, 95, 37-49 | 5.5 | 6 |
| 120 | Genetic markers of Restless Legs Syndrome in Parkinson disease. *Parkinsonism and Related Disorders*, **2015**, 21, 582-5 | 3.6 | 16 |
| 119 | Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene. *Movement Disorders*, **2015**, 30, 981-6 | 7 | 39 |
| 118 | Efficient Estimation of Nonparametric Genetic Risk Function with Censored Data. *Biometrika*, **2015**, 102, 515-532 | 2 | 4 |
| 117 | The emerging role of SMPD1 mutations in Parkinson disease: Implications for future studies. *Parkinsonism and Related Disorders*, **2015**, 21, 1294-5 | 3.6 | 26 |
| 116 | Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers. *Neurology*, **2015**, 84, 399-406 | 6.5 | 50 |

| | | | |
|---|---|---|---|
| 115 | Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. *JAMA Neurology*, **2015**, 72, 58-65 | 17.2 | 54 |
| 114 | GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder. *Annals of Clinical and Translational Neurology*, **2015**, 2, 941-5 | 5.3 | 95 |
| 113 | Neuropsychological performance in LRRK2 G2019S carriers with Parkinson disease. *Parkinsonism and Related Disorders*, **2015**, 21, 106-10 | 3.6 | 40 |
| 112 | A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson disease-related G2019S LRRK2 mutation carriers. *Movement Disorders*, **2014**, 29, 823-7 | 7 | 16 |
| 111 | Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes. *Human Molecular Genetics*, **2014**, 23, 4693-702 | 5.6 | 35 |
| 110 | Mechanism, prevalence, and more severe neuropathy phenotype of the Charcot-Marie-Tooth type 1A triplication. *American Journal of Human Genetics*, **2014**, 94, 462-9 | 11 | 36 |
| 109 | CHRNB3 c.-57A>G functional promoter change affects Parkinson disease and smoking. *Neurobiology of Aging*, **2014**, 35, 2179.e1-6 | 5.6 | 9 |
| 108 | Ethnic effect on FMR1 carrier rate and AGG repeat interruptions among Ashkenazi women. *Genetics in Medicine*, **2014**, 16, 940-4 | 8.1 | 10 |
| 107 | Two novel mutations identified in familial cases with Donohue syndrome. *Molecular Genetics & Genomic Medicine*, **2014**, 2, 64-72 | 2.3 | 20 |
| 106 | Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. *Genetics in Medicine*, **2014**, 16, 644-5 | 8.1 | 7 |
| 105 | Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 527-35 | 6.9 | 50 |
| 104 | Fall risk and gait in Parkinson disease: the role of the LRRK2 G2019S mutation. *Movement Disorders*, **2013**, 28, 1683-90 | 7 | 55 |
| 103 | Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. *Movement Disorders*, **2013**, 28, 1966-71 | 7 | 98 |
| 102 | Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers. *Cortex*, **2013**, 49, 2501-11 | 3.8 | 38 |
| 101 | The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. *Neurology*, **2013**, 80, 1606-10 | 6.5 | 113 |
| 100 | Single-channel properties of [illegible], [illegible] and [illegible] nicotinic acetylcholine receptors in mice lacking specific nicotinic acetylcholine receptor subunits. *Journal of Physiology*, **2013**, 591, 3271-88 | 3.9 | 13 |
| 99 | The age at motor symptoms onset in LRRK2-associated Parkinson disease is affected by a variation in the MAPT locus: a possible interaction. *Journal of Molecular Neuroscience*, **2012**, 46, 541-4 | 3.3 | 22 |
| 98 | Sperm epidermal growth factor receptor (EGFR) mediates [illegible] acetylcholine receptor (AChR) activation to promote fertilization. *Journal of Biological Chemistry*, **2012**, 287, 22328-40 | 5.4 | 18 |

| | | | |
|---|---|---|---|
| 97 | Undetected sex chromosome aneuploidy by chromosomal microarray. *Prenatal Diagnosis*, **2012**, 32, 1117-8 | 3.2 | 3 |
| 96 | A founder mutation causing a severe methylenetetrahydrofolate reductase (MTHFR) deficiency in Bukharian Jews. *Molecular Genetics and Metabolism*, **2012**, 107, 608-10 | 3.7 | 4 |
| 95 | Tnf, Cox2 and AdipoQ adipokine gene expression levels are modulated in murine adipose tissues by both nicotine and nACh receptors containing the 2 subunit. *Molecular Genetics and Metabolism*, **2012**, 107, 561-70 | 3.7 | 11 |
| 94 | Subunit composition of 5-containing nicotinic receptors in the rodent habenula. *Journal of Neurochemistry*, **2012**, 121, 551-60 | 6 | 20 |
| 93 | A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. *PLoS Genetics*, **2012**, 8, e1002559 | 6 | 117 |
| 92 | Lower cognitive performance in healthy G2019S LRRK2 mutation carriers. *Neurology*, **2012**, 79, 1027-32 | 6.5 | 55 |
| 91 | HIF1A C1772T polymorphism leads to HIF-1 mRNA overexpression in prostate cancer patients. *Cancer Biology and Therapy*, **2012**, 13, 720-6 | 4.6 | 20 |
| 90 | Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. *Brain*, **2012**, 135, 3687-98 | 11.2 | 30 |
| 89 | Association of sequence alterations in the putative promoter of RAB7L1 with a reduced parkinson disease risk. *Archives of Neurology*, **2012**, 69, 105-10 | | 48 |
| 88 | Fighting the risk of developing Parkinson's disease; clinical counseling for first degree relatives of patients with Parkinson's disease. *Journal of the Neurological Sciences*, **2011**, 310, 17-20 | 3.2 | 13 |
| 87 | Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease. *Neurogenetics*, **2011**, 12, 325-32 | 3 | 12 |
| 86 | The effects of aging vs. 7 nAChR subunit deficiency on the mouse brain transcriptome: aging beats the deficiency. *Age*, **2011**, 33, 1-13 | | 6 |
| 85 | Decreased expression of B cell related genes in leukocytes of women with Parkinson's disease. *Molecular Neurodegeneration*, **2011**, 6, 66 | 19 | 16 |
| 84 | Gait alterations in healthy carriers of the LRRK2 G2019S mutation. *Annals of Neurology*, **2011**, 69, 193-7 | 9.4 | 113 |
| 83 | 42 nicotinic acetylcholine receptors in the early postnatal mouse superior cervical ganglion. *Developmental Neurobiology*, **2011**, 71, 390-9 | 3.2 | 9 |
| 82 | Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia. *Leukemia and Lymphoma*, **2011**, 52, 642-7 | 1.9 | 5 |
| 81 | Large-scale population screening for spinal muscular atrophy: clinical implications. *Genetics in Medicine*, **2011**, 13, 110-4 | 8.1 | 23 |
| 80 | Biochemical and functional properties of distinct nicotinic acetylcholine receptors in the superior cervical ganglion of mice with targeted deletions of nAChR subunit genes. *European Journal of Neuroscience*, **2010**, 31, 978-93 | 3.5 | 47 |

| | | | |
|---|---|---|---|
| 79 | Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans. *Human Molecular Genetics*, **2010**, 19, 1998-2004 | 5.6 | 38 |
| 78 | False-positive results using a Gaucher diagnostic kit--RecTL and N370S. *Molecular Genetics and Metabolism*, **2010**, 100, 100-2 | 3.7 | 8 |
| 77 | Frequencies of C282Y and H63D alleles in the HFE gene among various Jewish ethnic groups in Israel: a change of concept required. *Genetics in Medicine*, **2010**, 12, 122-5 | 8.1 | 3 |
| 76 | Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. *Journal of Immunology*, **2009**, 183, 6681-8 | 5.3 | 206 |
| 75 | Dynamic modification strategy of the Israeli carrier screening protocol: inclusion of the Oriental Jewish Group to the cystic fibrosis panel. *Genetics in Medicine*, **2009**, 11, 101-3 | 8.1 | 5 |
| 74 | Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries. *Neurogenetics*, **2009**, 10, 355-8 | 3 | 19 |
| 73 | The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. *Journal of Neural Transmission*, **2009**, 116, 1473-82 | 4.3 | 40 |
| 72 | Being "at-risk" for developing cancer: cognitive representations and psychological outcomes. *Journal of Behavioral Medicine*, **2009**, 32, 197-208 | 3.6 | 26 |
| 71 | Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors. *Prostate*, **2009**, 69, 1034-44 | 4.2 | 14 |
| 70 | Genetic testing in Israel: an overview. *Annual Review of Genomics and Human Genetics*, **2009**, 10, 175-92 | 9.7 | 51 |
| 69 | The Predictive Value of TP53 FISH Analysis for Treatment Response and Survival in Cytogenetic Subgroups of AML Patients.. *Blood*, **2009**, 114, 2617-2617 | 2.2 | |
| 68 | Cytogenetic analysis of 101 skull base tumors. *Head and Neck*, **2008**, 30, 567-81 | 4.2 | 5 |
| 67 | Advances in the genetics of Parkinson's disease. *Acta Pharmacologica Sinica*, **2008**, 29, 21-34 | 8 | 20 |
| 66 | FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5'CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes. *Genes Chromosomes and Cancer*, **2007**, 46, 1028-38 | 5 | 44 |
| 65 | The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer. *Prostate*, **2007**, 67, 8-13 | 4.2 | 42 |
| 64 | Differential brain transcriptome of beta4 nAChR subunit-deficient mice: is it the effect of the null mutation or the background strain?. *Physiological Genomics*, **2007**, 28, 213-22 | 3.6 | 12 |
| 63 | Expression changes in mouse brains following nicotine-induced seizures: the modulation of transcription factor networks. *Physiological Genomics*, **2007**, 30, 242-52 | 3.6 | 10 |
| 62 | Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases. *JAMA - Journal of the American Medical Association*, **2007**, 298, 1281-90 | 27.4 | 56 |

| | | | |
|---|---|---|---|
| 61 | Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate. *Neoplasia*, **2007**, 9, 707-15 | 6.4 | 22 |
| 60 | Array-based comparative genome hybridization in clinical genetics. *Pediatric Research*, **2006**, 60, 353-8 | 3.2 | 23 |
| 59 | RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 474-9 | 4 | 22 |
| 58 | Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 3770-4 | 11.5 | 74 |
| 57 | An alternative spliced RNASEL variant in peripheral blood leukocytes. *Journal of Interferon and Cytokine Research*, **2006**, 26, 820-6 | 3.5 | 4 |
| 56 | Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. *Neoplasia*, **2006**, 8, 332-43 | 6.4 | 45 |
| 55 | Cytogenetic analysis of sinonasal carcinomas. *Otolaryngology - Head and Neck Surgery*, **2006**, 134, 654-60 | 5.5 | 13 |
| 54 | Mutation screening and association study of the candidate prostate cancer susceptibility genes MSR1, PTEN, and KLF6. *Prostate*, **2006**, 66, 1052-60 | 4.2 | 24 |
| 53 | Initial experience of videocapsule endoscopy for diagnosing small-bowel tumors in patients with GI polyposis syndromes. *Gastrointestinal Endoscopy*, **2005**, 62, 448-52 | 5.2 | 30 |
| 52 | Lower core body temperature and attenuated nicotine-induced hypothermic response in mice lacking the beta4 neuronal nicotinic acetylcholine receptor subunit. *Brain Research Bulletin*, **2005**, 66, 30-6 | 3.9 | 25 |
| 51 | Hidden function of neuronal nicotinic acetylcholine receptor beta2 subunits in ganglionic transmission: comparison to alpha5 and beta4 subunits. *Journal of the Neurological Sciences*, **2005**, 228, 167-77 | 3.2 | 8 |
| 50 | Increased severity of experimental colitis in alpha 5 nicotinic acetylcholine receptor subunit-deficient mice. *NeuroReport*, **2005**, 16, 1123-7 | 1.7 | 50 |
| 49 | Selective deletion of the alpha5 subunit differentially affects somatic-dendritic versus axonally targeted nicotinic ACh receptors in mouse. *Journal of Physiology*, **2005**, 563, 119-37 | 3.9 | 29 |
| 48 | Mice lacking neuronal nicotinic acetylcholine receptor beta4-subunit and mice lacking both alpha5- and beta4-subunits are highly resistant to nicotine-induced seizures. *Physiological Genomics*, **2004**, 17, 221-9 | 3.6 | 67 |
| 47 | A comparison between maternal serum free beta-human chorionic gonadotrophin and pregnancy-associated plasma protein A levels in first-trimester twin and singleton pregnancies. *Fetal Diagnosis and Therapy*, **2004**, 19, 174-7 | 2.4 | 12 |
| 46 | Cytogenetic analysis of three variants of clival chordoma. *Cancer Genetics and Cytogenetics*, **2004**, 154, 124-30 | | 19 |
| 45 | Multiplex nested PCR for preimplantation genetic diagnosis of spinal muscular atrophy. *Fetal Diagnosis and Therapy*, **2004**, 19, 199-206 | 2.4 | 21 |
| 44 | Nicotinic acetylcholine receptor alpha5 subunits modulate oxotremorine-induced salivation and tremor. *Journal of the Neurological Sciences*, **2004**, 222, 87-91 | 3.2 | 9 |

| | | | |
|---|---|---|---|
| 43 | Synergistic control of keratinocyte adhesion through muscarinic and nicotinic acetylcholine receptor subtypes. *Experimental Cell Research*, **2004**, 294, 534-49 | 4.2 | 59 |
| 42 | Deficiency of nicotinic acetylcholine receptor beta 4 subunit causes autonomic cardiac and intestinal dysfunction. *Molecular Pharmacology*, **2003**, 63, 574-80 | 4.3 | 36 |
| 41 | The nicotinic acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo. *Molecular Pharmacology*, **2003**, 63, 1059-66 | 4.3 | 167 |
| 40 | Combined cytogenetic and array-based comparative genomic hybridization analyses of Wilms tumors: amplification and overexpression of the multidrug resistance associated protein 1 gene (MRP1) in a metachronous tumor. *Cancer Genetics and Cytogenetics*, **2003**, 141, 120-7 | | 12 |
| 39 | Two novel translocations, t(2;4)(q35;q31) and t(X;12)(q22;q24), as the only karyotypic abnormalities in a malignant peripheral nerve sheath tumor of the skull base. *Cancer Genetics and Cytogenetics*, **2003**, 145, 139-43 | | 12 |
| 38 | The clinical application of spectral karyotyping (SKY) in the analysis of prenatally diagnosed extra structurally abnormal chromosomes (ESACs). *Prenatal Diagnosis*, **2003**, 23, 74-9 | 3.2 | 12 |
| 37 | Central role of fibroblast alpha3 nicotinic acetylcholine receptor in mediating cutaneous effects of nicotine. *Laboratory Investigation*, **2003**, 83, 207-25 | 5.9 | 82 |
| 36 | Functional role of alpha7 nicotinic receptor in physiological control of cutaneous homeostasis. *Life Sciences*, **2003**, 72, 2063-7 | 6.8 | 36 |
| 35 | Screening for familial dysautonomia in Israel: evidence for higher carrier rate among Polish Ashkenazi Jews. *Genetic Testing and Molecular Biomarkers*, **2003**, 7, 139-42 | | 31 |
| 34 | Molecular analysis of the APC gene in 71 Israeli families: 17 novel mutations. *Human Mutation*, **2002** , 19, 664 | 4.7 | 31 |
| 33 | MECP2 mutations in Israel: implications for molecular analysis, genetic counseling, and prenatal diagnosis in Rett syndrome. *Human Mutation*, **2002**, 20, 323-4 | 4.7 | 28 |
| 32 | Clinical and screening implications of the I1307K adenomatous polyposis coli gene variant in Israeli Ashkenazi Jews with familial colorectal neoplasia. Evidence for a founder effect. *Cancer*, **2002**, 94, 2561-8 | 6.4 | 28 |
| 31 | Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. *Prenatal Diagnosis*, **2002**, 22, 778-82 | 3.2 | 142 |
| 30 | Autonomic function in mice lacking alpha5 neuronal nicotinic acetylcholine receptor subunit. *Journal of Physiology*, **2002**, 542, 347-54 | 3.9 | 69 |
| 29 | Central role of alpha7 nicotinic receptor in differentiation of the stratified squamous epithelium. *Journal of Cell Biology*, **2002**, 159, 325-36 | 7.3 | 124 |
| 28 | Rett syndrome: clinical manifestations in males with MECP2 mutations. *Journal of Child Neurology*, **2002**, 17, 20-4 | 2.5 | 69 |
| 27 | First trimester maternal serum free human chorionic gonadotropin as a predictor of adverse pregnancy outcome. *Fetal Diagnosis and Therapy*, **2002**, 17, 352-6 | 2.4 | 55 |
| 26 | Increased sensitivity to nicotine-induced seizures in mice heterozygous for the L250T mutation in the alpha7 nicotinic acetylcholine receptor. *NeuroReport*, **2002**, 13, 191-6 | 1.7 | 20 |

| | | | |
|---|---|---|---|
| 25 | New genetic principles. *Clinical Obstetrics and Gynecology*, **2002**, 45, 593-604; discussion 730-2 | 1.7 | 5 |
| 24 | Maternal serum HCG is higher in the presence of a female fetus as early as week 3 post-fertilization. *Human Reproduction*, **2002**, 17, 485-9 | 5.7 | 47 |
| 23 | A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. *American Journal of Human Genetics*, **2002**, 71, 981-4 | 11 | 106 |
| 22 | The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. *Progress in Neurobiology*, **2002**, 68, 341-60 | 10.9 | 66 |
| 21 | Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. *Cancer Research*, **2002**, 62, 6803-7 | 10.1 | 90 |
| 20 | First trimester PAPP-A in the detection of non-Down syndrome aneuploidy. *Prenatal Diagnosis*, **2001**, 21, 547-9 | 3.2 | 15 |
| 19 | Effect of fetal gender on first trimester markers and on Down syndrome screening. *Prenatal Diagnosis*, **2001**, 21, 1027-30 | 3.2 | 36 |
| 18 | Novel mutations in the emerin gene in Israeli families. *Human Mutation*, **2001**, 17, 522 | 4.7 | 6 |
| 17 | Familial adenomatous polyposis at the Tel Aviv Medical Center: demographic and clinical features. *Familial Cancer*, **2001**, 1, 75-82 | 3 | 14 |
| 16 | Normal apoptosis levels in mice expressing one alpha7 nicotinic receptor null and one L250T mutant allele. *NeuroReport*, **2001**, 12, 1643-8 | 1.7 | 12 |
| 15 | Mice homozygous for the L250T mutation in the alpha7 nicotinic acetylcholine receptor show increased neuronal apoptosis and die within 1 day of birth. *Journal of Neurochemistry*, **2000**, 74, 2154-66 | 6 | 102 |
| 14 | The risk of fragile X premutation expansion is lower in carriers detected by general prenatal screening than in carriers from known fragile X families. *Genetic Testing and Molecular Biomarkers*, **2000**, 4, 289-92 | | 26 |
| 13 | Altered baroreflex responses in alpha7 deficient mice. *Behavioural Brain Research*, **2000**, 113, 3-10 | 3.4 | 63 |
| 12 | Multiorgan autonomic dysfunction in mice lacking the beta2 and the beta4 subunits of neuronal nicotinic acetylcholine receptors. *Journal of Neuroscience*, **1999**, 19, 9298-305 | 6.6 | 239 |
| 11 | Fetal muscle biopsy as a diagnostic tool in Duchenne muscular dystrophy. *Prenatal Diagnosis*, **1999**, 19, 921-6 | 3.2 | 11 |
| 10 | Prevalence of the I1307K APC gene variant in Israeli Jews of differing ethnic origin and risk for colorectal cancer. *Gastroenterology*, **1999**, 116, 54-7 | 13.3 | 65 |
| 9 | The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. *American Journal of Human Genetics*, **1998**, 63, 272-4 | 11 | 29 |
| 8 | High frequency of a common Bloom syndrome Ashkenazi mutation among Jews of Polish origin. *Genetic Testing and Molecular Biomarkers*, **1998**, 2, 293-6 | | 39 |

| | | | |
|---|---|---|---|
| 7 | □ Nicotinic Receptor Subunits Are Not Necessary for Hippocampal-Dependent Learning or Sensorimotor Gating: A Behavioral Characterization of Acra7-Deficient Mice. *Learning and Memory*, **1998**, 5, 302-316 | 2.8 | 216 |
| 6 | Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. *Journal of Neuroscience*, **1997**, 17, 9165-71 | 6.6 | 448 |
| 5 | Constitutional mosaicism for a chromosome 9 inversion resulting in recombinant aneusomy in an offspring **1997**, 69, 360-364 | | 8 |
| 4 | Segregation of a paternal insertional translocation results in partial 4q monosomy or 4q trisomy in two siblings. *American Journal of Medical Genetics Part A*, **1996**, 61, 10-5 | | 5 |
| 3 | Analysis of the Hoxd-3 gene: structure and localization of its sense and natural antisense transcripts. *DNA and Cell Biology*, **1995**, 14, 295-304 | 3.6 | 20 |
| 2 | Cloning and mapping of the mouse alpha 7-neuronal nicotinic acetylcholine receptor. *Genomics*, **1995**, 26, 399-402 | 4.3 | 33 |
| 1 | Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). *Developmental Biology*, **1993**, 158, 475-86 | 3.1 | 470 |